Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation

Eric A. Wiebke, Neil A. Grieshop, Richard A. Sidner, Thomas Howard, Suijin Yang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: L-Arginine has been described as a potential immunostimulant in vitro and in vivo. Excessive arginine, however, may be counterproductive. Data support the concept of minimal arginine requirements for normal lymphocyte proliferation, but the results of supplementation with pharmacologic doses of arginine have been contradictory. We hypothesized that excessive arginine supplementation might result in a blunting of normal immune responses of human lymphocytes in vitro. Materials and Methods: Peripheral blood mononuclear and T-cells were isolated from normal human donors. Cells were cultured in complete media with various concentrations of L-arginine, L-ornithine, and glycine. Lymphocytes were then stimulated with PHA or alloantigens, and proliferation was determined by measuring [3H]thymidine incorporation. Results: Lymphocyte proliferation was inhibited by L-arginine at pharmacologic doses. The effects were completely reversible. This inhibition could not be prevented by lymphocyte stimulation with IL-2, lymphocyte proliferation was more sensitive to inhibition by lower doses of arginine when alloantigens from irradiated fresh tumor cells or allogeneic lymphocytes were the stimuli. Finally, lymphocytes showed variable sensitivity to inhibition of proliferation in response to mitogen when treated with L-ornithine (little to no effect) or L-arginine (consistent inhibition at high doses). Pharmacologic doses of L-arginine result in reversible inhibition of normal lymphocyte proliferation in response to both mitogen and alloantigen. This inhibition could not be blocked by interleukin- 2. Conclusions: We conclude that caution should be exercised when recommending aggressive L-arginine supplementation as a possible method to reverse clinical immunosuppression caused by cancer, malnutrition, or trauma.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalJournal of Surgical Research
Volume70
Issue number1
DOIs
StatePublished - Jun 1997
Externally publishedYes

Fingerprint

Arginine
Lymphocytes
Isoantigens
Ornithine
Mitogens
Interleukin-2
Immunologic Adjuvants
Lymphocyte Activation
Malnutrition
Glycine
Immunosuppression
Thymidine
Cultured Cells
Neoplasms
T-Lymphocytes
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation. / Wiebke, Eric A.; Grieshop, Neil A.; Sidner, Richard A.; Howard, Thomas; Yang, Suijin.

In: Journal of Surgical Research, Vol. 70, No. 1, 06.1997, p. 89-94.

Research output: Contribution to journalArticle

Wiebke, Eric A. ; Grieshop, Neil A. ; Sidner, Richard A. ; Howard, Thomas ; Yang, Suijin. / Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation. In: Journal of Surgical Research. 1997 ; Vol. 70, No. 1. pp. 89-94.
@article{12b458d81b2c44089c1aaf5b6fe8347e,
title = "Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation",
abstract = "Background: L-Arginine has been described as a potential immunostimulant in vitro and in vivo. Excessive arginine, however, may be counterproductive. Data support the concept of minimal arginine requirements for normal lymphocyte proliferation, but the results of supplementation with pharmacologic doses of arginine have been contradictory. We hypothesized that excessive arginine supplementation might result in a blunting of normal immune responses of human lymphocytes in vitro. Materials and Methods: Peripheral blood mononuclear and T-cells were isolated from normal human donors. Cells were cultured in complete media with various concentrations of L-arginine, L-ornithine, and glycine. Lymphocytes were then stimulated with PHA or alloantigens, and proliferation was determined by measuring [3H]thymidine incorporation. Results: Lymphocyte proliferation was inhibited by L-arginine at pharmacologic doses. The effects were completely reversible. This inhibition could not be prevented by lymphocyte stimulation with IL-2, lymphocyte proliferation was more sensitive to inhibition by lower doses of arginine when alloantigens from irradiated fresh tumor cells or allogeneic lymphocytes were the stimuli. Finally, lymphocytes showed variable sensitivity to inhibition of proliferation in response to mitogen when treated with L-ornithine (little to no effect) or L-arginine (consistent inhibition at high doses). Pharmacologic doses of L-arginine result in reversible inhibition of normal lymphocyte proliferation in response to both mitogen and alloantigen. This inhibition could not be blocked by interleukin- 2. Conclusions: We conclude that caution should be exercised when recommending aggressive L-arginine supplementation as a possible method to reverse clinical immunosuppression caused by cancer, malnutrition, or trauma.",
author = "Wiebke, {Eric A.} and Grieshop, {Neil A.} and Sidner, {Richard A.} and Thomas Howard and Suijin Yang",
year = "1997",
month = "6",
doi = "10.1006/jsre.1997.5082",
language = "English (US)",
volume = "70",
pages = "89--94",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation

AU - Wiebke, Eric A.

AU - Grieshop, Neil A.

AU - Sidner, Richard A.

AU - Howard, Thomas

AU - Yang, Suijin

PY - 1997/6

Y1 - 1997/6

N2 - Background: L-Arginine has been described as a potential immunostimulant in vitro and in vivo. Excessive arginine, however, may be counterproductive. Data support the concept of minimal arginine requirements for normal lymphocyte proliferation, but the results of supplementation with pharmacologic doses of arginine have been contradictory. We hypothesized that excessive arginine supplementation might result in a blunting of normal immune responses of human lymphocytes in vitro. Materials and Methods: Peripheral blood mononuclear and T-cells were isolated from normal human donors. Cells were cultured in complete media with various concentrations of L-arginine, L-ornithine, and glycine. Lymphocytes were then stimulated with PHA or alloantigens, and proliferation was determined by measuring [3H]thymidine incorporation. Results: Lymphocyte proliferation was inhibited by L-arginine at pharmacologic doses. The effects were completely reversible. This inhibition could not be prevented by lymphocyte stimulation with IL-2, lymphocyte proliferation was more sensitive to inhibition by lower doses of arginine when alloantigens from irradiated fresh tumor cells or allogeneic lymphocytes were the stimuli. Finally, lymphocytes showed variable sensitivity to inhibition of proliferation in response to mitogen when treated with L-ornithine (little to no effect) or L-arginine (consistent inhibition at high doses). Pharmacologic doses of L-arginine result in reversible inhibition of normal lymphocyte proliferation in response to both mitogen and alloantigen. This inhibition could not be blocked by interleukin- 2. Conclusions: We conclude that caution should be exercised when recommending aggressive L-arginine supplementation as a possible method to reverse clinical immunosuppression caused by cancer, malnutrition, or trauma.

AB - Background: L-Arginine has been described as a potential immunostimulant in vitro and in vivo. Excessive arginine, however, may be counterproductive. Data support the concept of minimal arginine requirements for normal lymphocyte proliferation, but the results of supplementation with pharmacologic doses of arginine have been contradictory. We hypothesized that excessive arginine supplementation might result in a blunting of normal immune responses of human lymphocytes in vitro. Materials and Methods: Peripheral blood mononuclear and T-cells were isolated from normal human donors. Cells were cultured in complete media with various concentrations of L-arginine, L-ornithine, and glycine. Lymphocytes were then stimulated with PHA or alloantigens, and proliferation was determined by measuring [3H]thymidine incorporation. Results: Lymphocyte proliferation was inhibited by L-arginine at pharmacologic doses. The effects were completely reversible. This inhibition could not be prevented by lymphocyte stimulation with IL-2, lymphocyte proliferation was more sensitive to inhibition by lower doses of arginine when alloantigens from irradiated fresh tumor cells or allogeneic lymphocytes were the stimuli. Finally, lymphocytes showed variable sensitivity to inhibition of proliferation in response to mitogen when treated with L-ornithine (little to no effect) or L-arginine (consistent inhibition at high doses). Pharmacologic doses of L-arginine result in reversible inhibition of normal lymphocyte proliferation in response to both mitogen and alloantigen. This inhibition could not be blocked by interleukin- 2. Conclusions: We conclude that caution should be exercised when recommending aggressive L-arginine supplementation as a possible method to reverse clinical immunosuppression caused by cancer, malnutrition, or trauma.

UR - http://www.scopus.com/inward/record.url?scp=0031171786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031171786&partnerID=8YFLogxK

U2 - 10.1006/jsre.1997.5082

DO - 10.1006/jsre.1997.5082

M3 - Article

C2 - 9228934

AN - SCOPUS:0031171786

VL - 70

SP - 89

EP - 94

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -